NetraAI
Clinical trial AI
A next-generation AI solution for clinical trials.
Learn more
NetraMark
AITSX: AIAIToronto, ON
Builds NetraAI, a machine-learning platform that analyzes clinical trial datasets to identify patient subpopulations and patterns in treatment efficacy, toxicity and placebo response for drug sponsors.
Canadian innovation builds a brighter tomorrow.
About
Company site: netramark.comBuilds NetraAI, a machine-learning platform that analyzes clinical trial datasets to identify patient subpopulations and patterns in treatment efficacy, toxicity and placebo response for drug sponsors.
Listed on the Toronto Stock Exchange as AIAI, with additional OTCQB (AINMF) and Frankfurt (PF0) listings. netramark.com
Reported approximately C$3.415M in new contract bookings in fiscal 2026, a record annual high (August 2026). manilatimes.net
Signed its first contract flowing through a contract research organization partner, to analyze Phase 2 neurodegeneration trial data (July 2026). finance.yahoo.com
Held a non-binding Critical Path Innovation Meeting with the U.S. FDA on NetraAI; the FDA did not endorse or approve the platform. manilatimes.net
Products & Services
Company site: netramark.comProducts NetraMark publishes on its own site. Each card links to the page it was taken from.
Attractor AI
Causal inference
Provides machine learning algorithms with the power of causal inference through look-back memory technology.
SourcePeople
Sourced from the company's own pages or announcements.
George Achilleos
Chief Executive Officer
Joseph Geraci
Founder, Chief Scientific and Technical Officer
Josh Spiegel
President
Similar Companies
Other companies in AI.
